Pharmacologic treatments of dementia

Medical Clinics of North America

Volumn 86, Issue 3, 2002, Pages 657-674

  Bonner, Lauren T ^a   Peskind, Elaine R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIEMETIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; KETOCONAZOLE; QUINIDINE; RIVASTIGMINE; SELEGILINE; TACRINE;

ALZHEIMER DISEASE; ANOREXIA; CAREGIVER; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DEMENTIA; DEPRESSION; DIARRHEA; DISABILITY; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; HUMAN; LEWY BODY; MULTIINFARCT DEMENTIA; NAUSEA; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STANDARD; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT PLANNING; VOMITING;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; GINKGO BILOBA; HUMANS; PHYTOTHERAPY; PLANT PREPARATIONS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 0036323077     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00007-X     Document Type: Review

References (80)

1. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society
2. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop
3. Estimated prevalence of Alzheimer's disease in the United States
4. The effects of donepezil in Alzheimer's disease-results from a multinational trial
5. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
6. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease
7. A controlled trial of tacrine in Alzheimer's disease
8. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
9. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
10. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
11. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study
12. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
13. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
14. A 5-month randomized placebo-controlled trial of galantamine in AD
15. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial
16. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease The Alzheimer's Disease Cooperative Study
17. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain
18. A cholinergic connection between normal aging and senile dementia in the human hippocampus
19. Neurochemical characteristics of early and late onset types of Alzheimer's disease
20. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
21. Selective loss of central cholinergic neurons in Alzheimer's disease
22. Neurotransmitter changes in early- and late-onset Alzheimer-type dementia
23. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease
24. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases
25. Nicotinic acetylcholine binding sites in Alzheimer's disease
26. Alzheimer's disease: Clinical effects of lecithin treatment
27. Clinical effects of choline in Alzheimer's disease
28. Choline chloride treatment of memory deficits in the elderly
29. Effects of physostigmine and lecithin on memory in Alzheimer disease
30. Human serial learning: Enhancement with arecoline and choline impairment with scopolamine
31. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations
32. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
33. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician
34. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
35. A new rating scale for Alzheimer's disease
36. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
37. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
38. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
39. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
40. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
41. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
42. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease
43. Donepezil: An anticholinesterase inhibitor for Alzheimer's disease
44. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
45. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor
46. Preferential cerebrospinal fluid acetylcholi-nesterase inhibition by rivastigmine in humans
47. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
48. Rivastigmine. A review of its use in Alzheimer's disease
49. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
50. Measurement of quality-of-life changes in patients with Alzheimer's disease
51. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
52. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
53. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR
54. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6
55. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia
56. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease
57. Oxygen radicals in the nervous system
58. Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus
59. Involvement of free radicals in dementia of the Alzheimer type: A hypothesis
60. Alpha-tocopherol, an effective inhibitor of platelet adhesion
61. Vitamin E, a modifier of platelet function: Rationale and use in cardiovascular and cerebrovascular disease
62. Coagulopathy associated with vitamin E ingestion
63. Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency
64. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide
65. Ginkgo biloba leaf extract: Review of biological actions and clinical applications
66. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia
67. Development and validation of the geriatric evaluation by relatives rating instrument (GERRI)
68. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
69. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
70. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease
71. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease
72. Tacrine efficacy in Lewy body dementia
73. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
74. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
75. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
76. Prevention of vascular dementia
77. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention, and treatment